Article
STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Human cell - 1 Nov 2021
Wang Qian, Lu Bing, Zhang Yi, Yu Jing, Guo Jie, Zhou Qianchi, Lv Hong, Sun Yifeng
Abstract excerpt
Gefitinib is known as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) while an increasing number of patients with non-small cell lung cancer (NSCLC) are becoming resistant to EGFR-TKI. Therefore, innovative methods are urgently needed to overcome primary and acquired resista...
Topics
- Antineoplastic Agents
- Apoptosis
- Benzofurans
- Cell Line, Tumor
- Cell Movement
- Drug Resistance, Neoplasm
- Drug Synergism
- ErbB Receptors
- Gefitinib
- Gene Expression
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms
- Multidrug Resistance-Associated Proteins
- Mutation
- Naphthoquinones
- Neoplasm Invasiveness
- Protein Kinase Inhibitors